Can Yeast Be The Future Of Large Scale And Efficient Subunit Vaccine Manufacturing?

By Lisa Yu and Devarshi Kapadia

Vaccines have been developed at record breaking speeds to fight the COVID-19 pandemic and are already saving lives¹. At the time of writing, over 2.55 billion COVID-19 vaccine² doses have been administered globally and are paving the way to a return to a "new normal." However, there is still a pressing need to develop more vaccine options to further increase global access, and prepare for future infectious disease challenges. To aid in the manufacturing of new vaccines, Pichia pastoris yeast, a promising protein expression system, could be the perfect solution.